カテゴリ： GlobalData, アメリカ, 企業調査

Sunovion Pharmaceuticals Inc-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Sunovion Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013435
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月28日
◆ページ数：80
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Sunovion Pharmaceuticals Inc (Sunovion), a subsidiary of Sumitomo Dainippon Pharma Co Ltd, is a research-based pharmaceutical company. It discovers, develops and commercializes therapeutic products that focus on the treatment of central nervous system and respiratory disorders. Its product portfolio includes eslicarbazepine acetate tablets, lurasidone HCl tablets, eszopiclone tablets, levalbuterol HCl inhalation solution, levalbuterol tartrate inhalation aerosol, arformoterol tartrate inhalation solution, ciclesonide nasal spray, ciclesonide inhalation aerosol and ciclesonide nasal aerosol. The existing product portfolio and the pipeline candidates are targeted for treating patients of epilepsy, anxiety, depression, asthma, pain, allergic rhinitis and chronic obstructive pulmonary diseases. Sunovion’s major customers include medical institutions, hospitals and general public. Sunovion is headquartered in Marlborough, Massachusetts, the US.

Sunovion Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Sunovion Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Matrizyme Pharma Raises USD9 Million in Financing 13
Elevation Pharma Secures US$30 Million In Series B Financing 14
Elevation Pharma Secures US$17 Million In Second Tranche Of Series A Financing 16
Private Equity 18
Orbimed Advisors Acquires Additional 3.17% Stake in Cynapsus Therapeutics for USD6.3 Million 18
Partnerships 19
ex scientia Enters into Research Agreement with Sunovion Pharma 19
Sunovion Pharma Enters Into Agreement With Afraxis To Discover CNS Drugs 20
PsychoGenics Extends Drug Discovery Agreement with Sunovion Pharma 21
Prasco Labs Enters into Distribution Agreement with Sunovion Pharma for Xopenex 22
Licensing Agreements 23
Angelini Enters into Licensing and Distribution Agreement with Sunovion Pharma 23
Sunovion Pharma Enters into Licensing Agreement with Novartis 24
Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 25
Equity Offering 26
Cynapsus Therapeutics Raises USD72.5 Million in Public Offering of Shares 26
Cynapsus Therapeutics Raises USD16.6 Million in Private Placement of Shares 28
Cynapsus Therapeutics Completes Public Offering Of Units For US$22.8 Million 30
Cynapsus Therapeutics Completes Second Tranche Of Private Placement Of Units For US$1.3 Million 31
Cynapsus Therapeutics Completes Private Placement Of Units For US$1 Million 33
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.2 Million 34
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.1 Million 35
Cynapsus Therapeutics Postpones Private Placement Of US$10.5 Million 36
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.29 Million 37
Debt Offering 38
Cynapsus Therapeutics Completes Additional Public Offering Of Series E Debentures Due 2013 For US$1.1 Million 38
Cynapsus Therapeutics Completes Public Offering Of Secured Series D Debentures For US$0.51 Million 40
Cynapsus Therapeutics Completes Public Offering Of Secured Series C Debentures For US$0.3 Million 41
Asset Transactions 42
Sunovion Pharma to Divest US Rights of Ciclesonide Products to Covis Pharma 42
Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 43
Acquisition 44
Sunovion Pharma Acquires Cynapsus Therapeutics for up to USD635 Million 44
Sunovion Pharma Completes Acquisition Of Elevation Pharma For Up To US$430 Million 46
Cynapsus Therapeutics Completes Acquisition Of Adagio Pharma 48
Sunovion Pharmaceuticals Inc – Key Competitors 49
Sunovion Pharmaceuticals Inc – Key Employees 50
Sunovion Pharmaceuticals Inc – Locations And Subsidiaries 51
Head Office 51
Other Locations & Subsidiaries 51
Recent Developments 52
Product News 52
10/13/2016: Sunovion Announces FDA Filing Acceptance of New Drug Application for SUN-101/eFlow for the Treatment of Patients with Chronic Obstructive Pulmonary Disease 52
06/21/2016: Cynapsus Therapeutics Announces Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders 54
05/30/2016: Cynapsus Therapeutics Announces Data Presentations at the European Academy of Neurology Annual Meeting 56
04/04/2016: PsychoGenics Drug Discovery Collaboration with Sunovion Achieves a Milestone 57
Product Approvals 58
Jun 30, 2017: Sunovion Announces FDA Acceptance for Review of New Drug Application Resubmission for SUN-101/eFlow (glycopyrrolate) for the Treatment of Chronic Obstructive Pulmonary Disease 58
Jun 12, 2017: PsychoGenics Achieves a Milestone in Drug Discovery Collaboration with Sunovion 59
May 26, 2017: Sunovion Receives Complete Response Letter from FDA for SUN-101/eFlow (glycopyrrolate) New Drug Application for Chronic Obstructive Pulmonary Disease 60
Jul 29, 2016: Sunovion Submits New Drug Application for SUN-101/eFlow to the FDA for the Treatment of Patients with Chronic Obstructive Pulmonary Disease 61
Clinical Trials 62
May 23, 2017: Sunovion Presents Phase 3 Data Showing Safety, Efficacy and Improvement in Quality of Life Outcomes in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease Treated with SUN-101/eFlow (glycopyrrolate) 62
Aug 29, 2016: Cynapsus Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson’s Disease 64
Aug 15, 2016: Cynapsus Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson’s Disease Clinical Study Allowing for At-Home Titration 65
Aug 12, 2016: Cynapsus Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson’s Disease 66
Jul 22, 2016: Sunovion Announces Results of Phase 3 Long-Term Safety Study Showing SUN-101/eFlow (glycopyrrolate) Was Well-Tolerated in People with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease (COPD) 67
Jul 18, 2016: Cynapsus Therapeutics Announces Positive Phase 3 Dose Titration Phase Results with APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson’s Disease 69
Jul 18, 2016: Cynapsus Therapeutics Provides European Clinical Update for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson’s Disease 71
Jun 07, 2016: PARI Pharma’s Investigational Closed eFlow Nebulizer System Used in Two Successful Phase 3 Clinical Studies Evaluating Sunovion’s SUN-101 (glycopyrrolate) in People with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease 72
Apr 27, 2016: Sunovion Pharmaceuticals Announces Positive Results from Two Phase 3 Clinical Studies Evaluating SUN-101/eFlow (glycopyrrolate) in People with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease 73
Apr 15, 2016: Cynapsus Therapeutics Announces Data Presentations at the American Academy of Neurology Annual Meeting 75
Jan 25, 2016: Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline 76
Jan 07, 2016: Cynapsus and Michael J. Fox Foundation Collaborate on Pilot Use of Wearable Device and Data Science Approaches in Phase 3 Parkinson’s Clinical Study 77
Other Significant Developments 79
Dec 15, 2016: Sunovion Announces Collaboration with AMDA – The Society for Post-Acute and Long-Term Care Medicine 79
Appendix 80
Methodology 80
About GlobalData 80
Contact Us 80
Disclaimer 80

List of Tables
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Sunovion Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Sunovion Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Sunovion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Matrizyme Pharma Raises USD9 Million in Financing 13
Elevation Pharma Secures US$30 Million In Series B Financing 14
Elevation Pharma Secures US$17 Million In Second Tranche Of Series A Financing 16
Orbimed Advisors Acquires Additional 3.17% Stake in Cynapsus Therapeutics for USD6.3 Million 18
ex scientia Enters into Research Agreement with Sunovion Pharma 19
Sunovion Pharma Enters Into Agreement With Afraxis To Discover CNS Drugs 20
PsychoGenics Extends Drug Discovery Agreement with Sunovion Pharma 21
Prasco Labs Enters into Distribution Agreement with Sunovion Pharma for Xopenex 22
Angelini Enters into Licensing and Distribution Agreement with Sunovion Pharma 23
Sunovion Pharma Enters into Licensing Agreement with Novartis 24
Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 25
Cynapsus Therapeutics Raises USD72.5 Million in Public Offering of Shares 26
Cynapsus Therapeutics Raises USD16.6 Million in Private Placement of Shares 28
Cynapsus Therapeutics Completes Public Offering Of Units For US$22.8 Million 30
Cynapsus Therapeutics Completes Second Tranche Of Private Placement Of Units For US$1.3 Million 31
Cynapsus Therapeutics Completes Private Placement Of Units For US$1 Million 33
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.2 Million 34
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.1 Million 35
Cynapsus Therapeutics Postpones Private Placement Of US$10.5 Million 36
Cynapsus Therapeutics Completes Private Placement Of Units For US$0.29 Million 37
Cynapsus Therapeutics Completes Additional Public Offering Of Series E Debentures Due 2013 For US$1.1 Million 38
Cynapsus Therapeutics Completes Public Offering Of Secured Series D Debentures For US$0.51 Million 40
Cynapsus Therapeutics Completes Public Offering Of Secured Series C Debentures For US$0.3 Million 41
Sunovion Pharma to Divest US Rights of Ciclesonide Products to Covis Pharma 42
Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 43
Sunovion Pharma Acquires Cynapsus Therapeutics for up to USD635 Million 44
Sunovion Pharma Completes Acquisition Of Elevation Pharma For Up To US$430 Million 46
Cynapsus Therapeutics Completes Acquisition Of Adagio Pharma 48
Sunovion Pharmaceuticals Inc, Key Competitors 49
Sunovion Pharmaceuticals Inc, Key Employees 50
Sunovion Pharmaceuticals Inc, Other Locations 51
Sunovion Pharmaceuticals Inc, Subsidiaries 51

★海外企業調査レポート[Sunovion Pharmaceuticals Inc-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • NuGEN Technologies Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary NuGEN Technologies Inc (NuGEN) is a provider of biological science reagents. The company provides DNA and RNA sample preparation products for use in research and diagnostic applications. Its products include Next-Gen Sequencing applications, which include RNA-Seq, targeted resequencing of DN …
  • Medidata Solutions Inc (MDSO)：医療機器：M&Aディール及び事業提携情報
    Summary Medidata Solutions Inc (Medidata) is a provider of cloud based solutions for life sciences sectors. It offers wide range of advanced tools for data and analytics, planning, data capture, study management, monitoring, payments, and platform services. The company offers technology and data ana …
  • Healthcare Services Group Inc (HCSG)：企業の財務・戦略的SWOT分析
    Healthcare Services Group Inc (HCSG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • RockBridge Resources Inc (RBE)：石油・ガス：M&Aディール及び事業提携情報
    Summary RockBridge Resources Inc (RockBridge) is an oil and gas exploration and development company. The company acquires, develops and explores oil and gas properties. Its properties include Twinning area, Open Creek property, Pembina and Brazeau property, and Bigoray area of Alberta. RockBridge’s …
  • Luitpold Pharmaceuticals Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Luitpold Pharmaceuticals Inc (Luitpold Pharmaceuticals), a subsidiary of Daiichi Sankyo Co Ltd is a manufacturer and marketer of drugs and medical devices. The company provides products such as injectable parenteral medications that are used in pharmacy admixtures and nutrient solutions, cri …
  • Baker Hughes Incorporated：企業の戦略・SWOT・財務情報
    Baker Hughes Incorporated - Strategy, SWOT and Corporate Finance Report Summary Baker Hughes Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Bank of Ningbo Co. Ltd.：企業の戦略・SWOT・財務情報
    Bank of Ningbo Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Bank of Ningbo Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Medimetriks Pharmaceuticals Inc-製薬・医療分野：企業M&A・提携分析
    Summary Medimetriks Pharmaceuticals Inc (MPI) is a drug company that offers skincare products. The company provides personal care products including cleansers, nutritional suppliments, cosmetic creams, and moisturizer. Its products include Centany, Ciclodan, Clindacin ETZ, Genadur, Ketodan, Morgidox …
  • Debiopharm International SA-製薬・医療分野：企業M&A・提携分析
    Summary Debiopharm International SA (Debiopharm), a subsidiary of Debiopharm Group is a biopharmaceutical company that develops prescription drugs. The company offers a range of licensing and drug development solutions. It evaluates, searches, and in-licenses promising drug candidates for developmen …
  • Informa plc：企業の戦略・SWOT・財務情報
    Informa plc - Strategy, SWOT and Corporate Finance Report Summary Informa plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • PG&E Corp (PCG)：企業の財務・戦略的SWOT分析
    PG&E Corp (PCG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • German Cancer Research Center-医療機器分野：企業M&A・提携分析
    Summary German Cancer Research Center (DKFZ) is a biomedical research institute that develops therapies for the treatment of cancer patients. The institute’s research programs include translational cancer research, cell biology and tumor biology, imaging and radiooncology, cancer risk factors and pr …
  • Nostrum Oil & Gas PLC (NOG)：石油・ガス：M&Aディール及び事業提携情報
    Summary Nostrum Oil & Gas PLC (Nostrum) is an independent oil and gas company. It produces, develops, and explores for oil and gas in the pre-Caspian Basin. The company produces crude oil, stabilized liquid condensate, LPG and dry gas. Nostrum has commercial hydrocarbon reserves in the Ardatovski, L …
  • James Fisher and Sons Plc (FSJ)：石油・ガス：M&Aディール及び事業提携情報
    Summary James Fisher and Sons Plc (James Fisher) is a service provider for global marine industry and a specialist supplier of engineering services to the energy industry. The company provides comprehensive services such as design and engineering; inspection and monitoring; lifting and handling; mar …
  • Ophthotech Corp (OPHT)：企業の財務・戦略的SWOT分析
    Summary Ophthotech Corp (Ophthotech) is a biopharmaceutical company that develops novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company’s products include Zimura, a complement inhibitor for stargardt disease. It also provides Fovista, a …
  • Diasome Pharmaceuticals Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Diasome Pharmaceuticals Inc (Diasome) is a pharmaceutical company that focusses on clinical and commercial development of therapies for diabetes and obesity. The company offers products in the fields of cell receptor targeting, insulin replacement, and hepatic (liver) glucose metabolism. Its …
  • Lophius Biosciences GmbH：医療機器：M&Aディール及び事業提携情報
    Summary Lophius Biosciences GmbH (Lophius) is a biotechnology company that develops and markets T cell-based diagnostic systems and research tools in the areas of transplantation, infectious and autoimmune diseases. The company’s T-track immunoscan assay is a test in natural or induced immune modula …
  • Cardif Lux Vie S.A.：企業の戦略・SWOT・財務情報
    Cardif Lux Vie S.A. - Strategy, SWOT and Corporate Finance Report Summary Cardif Lux Vie S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Align Technology, Inc.：戦略・SWOT・企業財務分析
    Align Technology, Inc. - Strategy, SWOT and Corporate Finance Report Summary Align Technology, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Sime Darby Unimills B.V. ：企業の戦略・SWOT・財務情報
    Sime Darby Unimills B.V. - Strategy, SWOT and Corporate Finance Report Summary Sime Darby Unimills B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆